Morgan Stanley analyst Craig Hettenbach has maintained their neutral stance on HCA stock, giving a Hold rating on October 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Craig Hettenbach has given his Hold rating due to a combination of factors. Despite HCA Healthcare’s strong performance and execution, the potential for further stock price growth appears limited in the near term. The stock has already seen significant gains, outperforming both the S&P 500 Healthcare and the broader S&P 500 indices, suggesting a period of consolidation might be on the horizon.
Additionally, while the company has improved its EBITDA margins and is actively expanding its resiliency program, uncertainties remain. These include potential changes in federal policies and the impact of enhanced subsidies and exchange volumes. Furthermore, the company’s updated price target indicates a modest downside, reinforcing the Hold recommendation.
In another report released on October 16, Bernstein also maintained a Hold rating on the stock with a $417.00 price target.